Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2011 Apr 15;52(8):1053-7.
doi: 10.1093/cid/cir107.

HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study

Somnuek Sungkanuparph  1 , Rebecca Oyomopito, Sunee Sirivichayakul, Thira Sirisanthana, Patrick C K Li, Pacharee Kantipong, Christopher K C Lee, Adeeba Kamarulzaman, Liesl Messerschmidt, Matthew G Law, Praphan Phanuphak; TREAT Asia Studies to Evaluate Resistance-Monitoring Study (TASER-M)
Collaborators, Affiliations
Multicenter Study

HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study

Somnuek Sungkanuparph et al. Clin Infect Dis. .

Abstract

Of 682 antiretroviral-naïve patients initiating antiretroviral therapy in a prospective, multicenter human immunodeficiency virus type 1 (HIV-1) drug resistance monitoring study involving 8 sites in Hong Kong, Malaysia, and Thailand, the prevalence of patients with ≥1 drug resistance mutation was 13.8%. Primary HIV drug resistance is emerging after rapid scaling-up of antiretroviral therapy use in Asia.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Distribution of resistance-associated mutations among 682 antiretroviral-naïve human immunodeficiency virus type 1 (HIV-1)–infected patients.
See this image and copyright information in PMC

Comment in

References

    1. Joint United Nations Programme on HIV/AIDS and World Health Organization. AIDS epidemic update December 2009. WHO Library Cataloguing-in-Publication Data November 2009;
    1. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43:42–6. - PubMed
    1. Kumarasamy N, Solomon S, Chaguturu SK, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis. 2005;41:1525–8. - PubMed
    1. Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res. 2007;5:355–60. - PubMed
    1. Sungkanuparph S, Chakriyanuyok T, Butthum B. Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome. J Infect. 2008;56:40–3. - PubMed

Publication types

Substances